[go: up one dir, main page]

SG158133A1 - Method for reversing multiple resistance in animal cells - Google Patents

Method for reversing multiple resistance in animal cells

Info

Publication number
SG158133A1
SG158133A1 SG200908280-1A SG2009082801A SG158133A1 SG 158133 A1 SG158133 A1 SG 158133A1 SG 2009082801 A SG2009082801 A SG 2009082801A SG 158133 A1 SG158133 A1 SG 158133A1
Authority
SG
Singapore
Prior art keywords
animal cells
multiple resistance
reversing multiple
reversing
resistance
Prior art date
Application number
SG200908280-1A
Other languages
English (en)
Inventor
Per Sonne Holm
Original Assignee
Sonne Holm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonne Holm filed Critical Sonne Holm
Publication of SG158133A1 publication Critical patent/SG158133A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200908280-1A 2004-12-31 2006-01-02 Method for reversing multiple resistance in animal cells SG158133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004063639 2004-12-31
US65108505P 2005-02-08 2005-02-08

Publications (1)

Publication Number Publication Date
SG158133A1 true SG158133A1 (en) 2010-01-29

Family

ID=36582063

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200908280-1A SG158133A1 (en) 2004-12-31 2006-01-02 Method for reversing multiple resistance in animal cells

Country Status (10)

Country Link
US (4) US20100310554A1 (es)
EP (1) EP1831382B1 (es)
JP (1) JP5584393B2 (es)
KR (1) KR101527213B1 (es)
CN (1) CN101128593B (es)
AU (1) AU2006203736B2 (es)
CA (1) CA2592699C (es)
MX (1) MX2007008136A (es)
SG (1) SG158133A1 (es)
WO (1) WO2006070023A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099859A2 (de) 2002-05-27 2003-12-04 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
JP5435871B2 (ja) * 2004-12-31 2014-03-05 ホルム，ペル・ゾンネ Ｅ１−マイナスアデノウイルス及びその使用
WO2010068794A2 (en) * 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
EP2812012A1 (en) * 2012-02-07 2014-12-17 Global Bio Therapeutics USA, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
US10202568B2 (en) 2013-08-12 2019-02-12 Invivosciences Inc. Automated cell culture system and method
CN108064275A (zh) 2014-09-24 2018-05-22 萨克生物研究学院 溶瘤肿瘤病毒及使用方法
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
US10813957B2 (en) * 2016-10-07 2020-10-27 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
AU2018271999A1 (en) * 2017-05-24 2020-01-16 Epicentrx, Inc. Anti-angiogenic adenovirus
CN109576231B (zh) 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
CN113774031B (zh) * 2020-06-10 2024-04-02 广州恩宝生物医药科技有限公司 一种复制型人腺病毒及其应用
WO2023054671A1 (ja) * 2021-09-30 2023-04-06 富士フイルム株式会社 アデノ随伴ウイルスの製造方法、細胞および発現ベクター

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3827163B2 (ja) * 1995-03-24 2006-09-27 ジェンザイム・コーポレーション 遺伝子治療用のアデノウイルスベクター
AU2319497A (en) * 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
PT974668E (pt) * 1998-07-07 2003-01-31 Transgene Sa Utilizacao de blocos de leitura da regiao e4 adenoviral para melhorar a expressao de um gene relevante
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
DE19929569A1 (de) * 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
DE10031122A1 (de) * 1999-06-30 2001-03-22 Max Delbrueck Centrum Mittel zur Diagnose und Therapie maligner Erkrankungen
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
AU1087701A (en) * 1999-10-15 2001-04-30 Canji, Inc. Targeted vectors
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US20030095989A1 (en) * 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
KR100491299B1 (ko) * 2001-09-29 2005-05-24 학교법인연세대학교 개선된 질환 치료 효과를 갖는 재조합 아데노바이러스 및그를 포함하는 약제학적 조성물
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
KR101006594B1 (ko) * 2002-04-25 2011-01-07 크루셀 홀란드 비.브이. 안정한 아데노바이러스 벡터 및 그 증식 방법
WO2003099859A2 (de) * 2002-05-27 2003-12-04 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
MXPA05004074A (es) * 2002-10-15 2005-09-20 Sonne Holm Per Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
RU2393221C2 (ru) * 2002-10-15 2010-06-27 Пер Сонне ХОЛЬМ Аденовирус с обращенной генной экспрессией и его применение
CN1791679A (zh) * 2003-03-19 2006-06-21 伊索格尼斯股份有限公司 基于CD8α链的具有降低的免疫原性的基因治疗载体
EP1618223A2 (en) * 2003-04-28 2006-01-25 Nanosys, Inc. Super-hydrophobic surfaces, methods of their construction and uses therefor
CA2590257A1 (en) * 2003-11-14 2005-06-09 Per Sonne Holm Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2005051430A1 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
JP5435871B2 (ja) * 2004-12-31 2014-03-05 ホルム，ペル・ゾンネ Ｅ１−マイナスアデノウイルス及びその使用
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus

Also Published As

Publication number Publication date
CA2592699A1 (en) 2006-07-06
EP1831382A2 (en) 2007-09-12
JP5584393B2 (ja) 2014-09-03
MX2007008136A (es) 2008-02-12
EP1831382B1 (en) 2023-01-18
CA2592699C (en) 2023-02-21
US20110286999A1 (en) 2011-11-24
WO2006070023A3 (en) 2006-09-21
CN101128593A (zh) 2008-02-20
US20100310554A1 (en) 2010-12-09
US20170252443A1 (en) 2017-09-07
KR20070103412A (ko) 2007-10-23
US20220339219A1 (en) 2022-10-27
AU2006203736B2 (en) 2012-03-29
JP2008526188A (ja) 2008-07-24
AU2006203736A1 (en) 2006-07-06
US11369650B2 (en) 2022-06-28
CN101128593B (zh) 2014-09-03
KR101527213B1 (ko) 2015-06-09
WO2006070023A2 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
SG158133A1 (en) Method for reversing multiple resistance in animal cells
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
IL183940A0 (en) Glp-1 agonists, compositions, methods and uses
AP2289A (en) Microbial biocementation.
NO20053161D0 (no) Mikrobedrepende sammensetning.
DE602005022897D1 (de) Piperidinylamino-thienoä2,3-dü-pyrimidinverbindungen
FI20045162A0 (fi) Ryhmäviestintä viestinjärjestelmässä
DE502005007723D1 (de) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone,
ATE556446T1 (de) Batterieanoden
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
MX2008001638A (es) Metodo de espaciado de piel entumecida.
GB0413142D0 (en) Improvements in, or relating to testing
ITMI20051746A1 (it) Macchina i.s.
BR8203451Y1 (pt) disposição construtiva em copo descartável.
AU2004906102A0 (en) Softshu horseshoe Rev. I
ITFR20040018A1 (it) Antislavina & i.s.m.
UA4341U (uk) Літична суміш для проведення гібернації та гіпотермії
ES1056941Y (es) Percha multiple.
AU300905S (en) Storage unit
AU2005900374A0 (en) The fish hooka, new submission
NL1025973A1 (nl) Hengsel.
ITTV20040062A1 (it) Procedimento per l'ottenimento di tubazioni, in particolare per il contenimento di cavi.
AU300898S (en) Storge unit
GB0415035D0 (en) C.s.v.